Creating Psychedelic Analogs to Treat Neuropsychiatric Disease

• Prof. David Olson, Department of Chemistry, Department of Biochemistry & Molecular Medicine, UC Davis
• Sponsored by ACS Webinars, ACS Publications, ACS Division of Medicinal Chemistry, and American Association of Pharmaceutical Scientists
• 11am-Noon, Online via Zoom, Free, Registration required

We are at an exciting moment in drug discovery due to the enormous potential of psychedelics and related plasticity-promoting neurotherapeutics to treat common, but highly debilitating conditions such as schizophrenia, bipolar disorder, major depressive disorder, and attention deficit hyperactivity disorder.

Join Associate Professor Dr. David Olson of UC Davis as he discusses how psychedelics and related molecules, such as DMT, LSD, and MDMA, rapidly promote the growth of cortical neurons, providing a potential explanation for their long-lasting therapeutic effects after a single dose. Register now to discover about the development of chemical and molecular tools for studying the mechanisms of action of psychedelics as well as efforts to engineer non-hallucinogenic analogs of these compounds that produce similar sustained therapeutic behavioral effects after a single administration.

This ACS Webinar is moderated by Editor-in-Chief Dr. Christa Müller of ACS Pharmacology & Translational Science co-produced with the ACS Division of Medicinal Chemistry, and ACS Publications.